Business Context and Reporting Period
This Form 8-K, dated July 17, 2023 and signed July 18, 2023, was filed by Deep Medicine Acquisition Corp., a special purpose acquisition company (SPAC). The request metadata identifies Trugolf Holdings, Inc., but the filing’s registrant is Deep Medicine Acquisition Corp.; the relationship to Trugolf is not explained in the provided text.
Material Definitive Agreement
The company and Bright Vision Sponsor LLC entered into additional non-redemption agreements with unaffiliated investors in connection with the company’s July 13, 2023 special meeting. As of the filing date, six unaffiliated third parties had entered into such agreements.
- The agreements covered a maximum aggregate of 514,773 shares of Class A common stock originally sold in the company’s initial public offering.
- The sponsor agreed to transfer a maximum aggregate of 185,179 Class A common shares upon consummation of the company’s initial business combination.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, valuation, or other operating financial metrics.
Outlook, Risks, and Unusual Items
The non-redemption agreements appear intended to support the company’s shareholder base and reduce potential redemptions in connection with the business-combination process. The filing does not disclose the identity of the counterparties, consideration for the arrangements, the number of shares ultimately expected to remain outstanding, or whether the initial business combination will be completed.
Investor Verification Points
- Verify the correct registrant and the relationship, if any, between Deep Medicine Acquisition Corp. and Trugolf Holdings, Inc.
- Confirm the final number of shares subject to the non-redemption agreements and the sponsor’s actual share transfers.
- Review subsequent filings for the results of the July 13, 2023 special meeting, redemption levels, and the status of the initial business combination.
- Review the underlying non-redemption agreements for contractual terms, fees, transfer restrictions, and potential dilution.